Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

243.86USD
28 Apr 2017
Change (% chg)

$0.81 (+0.33%)
Prev Close
$243.05
Open
$243.09
Day's High
$244.15
Day's Low
$240.56
Volume
1,835,243
Avg. Vol
3,210,063
52-wk High
$261.27
52-wk Low
$184.50

AGN

Chart for AGN

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $81,814.13
Shares Outstanding(Mil.): 335.50
Dividend: 0.70
Yield (%): 1.15

Financials

  AGN Industry Sector
P/E (TTM): -- 29.08 30.08
EPS (TTM): -3.12 -- --
ROI: -0.75 13.73 13.25
ROE: -1.71 14.68 14.41

BRIEF-Allergan completes Zeltiq acquisition

* Allergan successfully completes zeltiq® aesthetics acquisition Source text for Eikon: Further company coverage:

Apr 28 2017

India watchdog orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 27 2017

UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug

MUMBAI, April 27 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 27 2017

BRIEF-Paratek Pharma, Zai Lab announce agreement

* Paratek Pharmaceuticals and Zai Lab announce collaboration, development and license agreement for omadacycline in China

Apr 24 2017

Allergan, Argentum settle patent dispute over eye drug Restasis

U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis.

Apr 18 2017

Allergan, Argentum settle patent dispute over eye drug Restasis

April 18 U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis.

Apr 18 2017

BRIEF-Argentum Pharmaceuticals, Allergan settle patent dispute over Restasis

* Argentum PHARMACEUTICALS and Allergan settle patent dispute over Restasis

Apr 18 2017

BRIEF-Novartis expands trials for NASH via collaboration with Allergan

* Novartis expands development programs for NASH through clinical collaboration with Allergan

Apr 18 2017

BRIEF-Allergan says it has entered into a clinical trial agreement with Novartis to conduct a phase 2b study

* Announced it has entered into a clinical trial agreement with Novartis to conduct a phase 2b study, using Allergan's Cenicriviroc

Apr 18 2017

Swiss billionaire Wyss gets nearly 10 percent of Molecular Partners

ZURICH Swiss billionaire Hansjoerg Wyss has built a nearly 10 percent stake in biotech group Molecular Partners after share sales by Johnson & Johnson and other investors, the SIX Swiss Exchange said on Tuesday.

Apr 11 2017

More From Around the Web

Earnings vs. Estimates